Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 5/20 | 0.64 |
| ▸ | GPR27 | Q9NS67 | 5/20 | 0.54 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2358814 | 0.91 | NR3C2 (0.63) | NR3C2GPR27AVPR2GAAALDH1A1 | |
| SCHEMBL2358561 | 0.89 | NR3C2 (0.79) | NR3C2GPR27AVPR2GAAALDH1A1 | |
| SCHEMBL2360022 | 0.89 | NR3C2 (0.82) | NR3C2GPR27AVPR2GAAPOLB | |
| SCHEMBL16457065 | 0.86 | NR3C2 (0.49) | NR3C2GPR27AVPR2GAAPOLB | |
| SCHEMBL2358694 | 0.82 | NR3C2 (0.79) | NR3C2GPR27AVPR2GAAALDH1A1 | |
| SCHEMBL27997694 | 0.82 | NR3C2 (0.79) | NR3C2GPR27AVPR2GAAALDH1A1 | |
| SCHEMBL2359411 | 0.82 | NR3C2 (0.71) | NR3C2GPR27AVPR2GAAALDH1A1 | |
| SCHEMBL2360207 | 0.81 | NR3C2 (0.68) | NR3C2GPR27AVPR2 | |
| SCHEMBL2359373 | 0.80 | NR3C2 (0.77) | NR3C2GPR27AVPR2GAAALDH1A1 | |
| SCHEMBL2357822 | 0.80 | NR3C2 (0.69) | NR3C2GPR27AVPR2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642640-B2 | 1-phenylpyrrole derivatives | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | claimed |
| EP-2349996-B1 | 1-PHENYLPYRROLE COMPOUNDS | EXELIXIS INC (US) | 2014-01-01 | — | — | EP | claimed |
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-10-27 | — | — | US | claimed |
| EP-2349996-A1 | 1-PHENYLPYRROLE COMPOUNDS | Exelixis, Inc. (US) | 2011-08-03 | — | — | EP | claimed |
| WO-2010042626-A1 | 1-PHENYLPYRROLE COMPOUNDS | EXELIXIS, INC. (US) | 2010-04-15 | — | — | WO | claimed |
| US-8642640-B2 | 1-phenylpyrrole derivatives | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642640-B2 | 1-phenylpyrrole derivatives | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642640-B2 | 1-phenylpyrrole derivatives | EXELIXIS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2349996-B1 | 1-PHENYLPYRROLE COMPOUNDS | EXELIXIS INC (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-2349996-B1 | 1-PHENYLPYRROLE COMPOUNDS | EXELIXIS INC (US) | 2014-01-01 | — | — | EP | disclosed |
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| EP-2349996-A1 | 1-PHENYLPYRROLE COMPOUNDS | Exelixis, Inc. (US) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010042626-A1 | 1-PHENYLPYRROLE COMPOUNDS | EXELIXIS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042626-A1 | 1-PHENYLPYRROLE COMPOUNDS | EXELIXIS, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263544-A1 | 1-Phenylpyrrole Derivatives | REN, AGTR1, NR3C2 | NR3C2 3/4885GPR27 637/4885AVPR2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.